Jun 04, 2026 | SCOTUS Backs Hikma Skinny-Label Win on Vascepa; ADC Therapeutics Crashes 50% on Death

SCOTUS unanimously backs Hikma's skinny-label Vascepa generic, reshaping patent defense for branded pharma. ADC Therapeutics drops 50%+ on LOTIS-5 death rate (13.2% vs 4.6%), biotech M&A crosses $106B in 2026, and Legend Biotech surges on in vivo CAR-T data.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Hikma, Amarin, Vascepa, skinny label, Supreme Court, generics, ADC Therapeutics, Zynlonta, loncastuximab tesirine, DLBCL, LOTIS-5, Legend Biotech, CAR-T, in vivo, Novo Nordisk, manufacturing, Kyle Diamantas, Merck, WELIREG, KEYTRUDA, Alnylam, Inceptive, Parabilis, Fulcrum, Celcuity, Axsome, Sunosi, biotech M&A, COINS Act, Otsuka, Voyxact, IgA nephropathy, Pfizer, Novartis, GSK